University of Florida Research Foundation Inc

Arizona State University

Genzyme Corporation

Mark A. Atkinson

Noel K. Maclaren

William Kastern

Mark A Atkinson

Noel K Maclaren

Clive Henry Wasserfall

Desmond A Schatz

Tamir M Ellis

Alba Esther Morales

Joshua LaBaer

Abraham Scaria

Donna Armentano

Benjamin George Keselowsky

Josef Neu

Ji Qiu

Graciela Liliana Lorca

Tracey Lodie

Joseph Larkin

Scott Eisenbeis

Young Mee Yoon

Xiaofang Bian

Eric W Triplett

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

Methods for diagnosis of type 1 diabetes

The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.

Materials and methods for modulating immune responses

The invention provides compositions for treating or preventing T1D (T1D), the compositions comprising one or more antigen presenting cells (APC) that have been pulsed with one or more bacteria and/or components of the bacteria, wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. The subject invention also provides a method of treating or preventing T1D in a subject, the method comprising administering APC that have been pulsed with one or more bacteria and/or components of the bacteria and wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells.

Compositions for treatment and/or prevention of autoimmune disorders

Isolatedstrains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising thestrains and use of the composition in T1D prevention are provided.

[object Object]

In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.

Combination therapies for treating type 1 diabetes

Biomarkers that are diagnostic of type 1 diabetes, type 2 diabetes and/or diabetic disorder are identified. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of type 1 diabetes, type 2 diabetes and/or diabetic disorder. An analysis includes the parameters of matching for BMI and Tanner stage. Receiver-operator characteristic (ROC) curves were established to assess association of the biomarkers with a disease.

Biomarkers for differentiating between type 1 and type 2 diabetes

The subject invention concerns a novel process for the early detection of insulin dependent diabetes (IDD). The novel process described here enables the detection of the onset of IDD before clinical symptoms appear. The novel process involves the detection, in a sample of biological fluid, of an autoantibody which is highly specific to individuals who will later develop the clinical manifestations of IDD. Novel treatments for the prevention of IDD are also described.

Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus

Compositions and methods for the treatment or prevention of insulin dependent diabetes (IDD) are provided. Specifically, glutamic acid decarboxylase (GAD) proteins, and fragments. thereof, can be administered to an animal in order to the reduce the severity of IDD.

Method and compositions for early detection and treatment of insulin

The invention pertains to the discovery of antigenic cross reactivity between a pancreatic 64K autoantigen and glutamic acid decarboxylase (GAD). Autoantibodies toward GAD were found to be associated with insulin dependent diabetes (IDD). More specifically, the invention pertains to the use of GAD for the diagnosis, prevention and treatment of insulin dependent diabetes (IDD).

Methods and compositions for the early detection and treatment of

The subject invention concerns a process for the early detection of insulin dependent diabetes (IDD). The process described here enables the detection of the onset of IDD before clinical symptoms appear. The process involves the detection, in a sample of biological fluid, of an autoantibody which is highly specific to individuals who will later develop the clinical manifestations of IDD. Novel treatments for the prevention of IDD are also described.

Growing community of inventors

Gainesville, FL, United States of America

Mark A Atkinson